Template:Ionotropic glutamate receptor modulators: Difference between revisions
From Vigyanwiki
No edit summary |
m (4 revisions imported from alpha:Template:Ionotropic_glutamate_receptor_modulators) |
||
| (4 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
{{Navbox | {{Navbox | ||
| name = | | name = Ionotropic glutamate receptor modulators | ||
| title = [[Ionotropic glutamate receptor]] [[receptor modulator|modulator]]s | |||
| state = {{{state<includeonly>|collapsed</includeonly>}}} | |||
| bodyclass = hlist | | bodyclass = hlist | ||
| groupstyle = text-align:center; | | groupstyle = text-align:center; | ||
| group1 = {{abbrlink|AMPAR|α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor}} | | group1 = {{abbrlink|AMPAR|α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor}} | ||
| list1 =* '' ' | | list1 = | ||
* [[ | * '''Agonists:''' ''Main site agonists:'' [[5-Fluorowillardiine]] | ||
* [[ | * [[Acromelic acid|Acromelic acid (acromelate)]] | ||
* [[β- | * [[AMPA]] | ||
* [[ | * [[β-N-Oxalylamino-L-Alanine|BOAA]] | ||
* [[ | * [[Domoic acid]] | ||
* [[ | * [[Glutamate]] | ||
* [[ | * [[Ibotenic acid]] | ||
* [[ | * [[Proline]] | ||
* [[ | * [[Quisqualic acid]] | ||
* [[ | * [[Willardiine]]; ''Positive allosteric modulators:'' [[Aniracetam]] | ||
* [[ | * [[Cyclothiazide]] | ||
* [[ | * [[CX-516]] | ||
* [[ | * [[CX-546]] | ||
* [[ | * [[CX614|CX-614]] | ||
* [[ | * [[Farampator|Farampator (CX-691, ORG-24448)]] | ||
* [[ | * [[CX717|CX-717]] | ||
* [[ | * [[CX-1739]] | ||
* [[ | * [[CX-1942]] | ||
* [[ | * [[Diazoxide]] | ||
* [[ | * [[Hydrochlorothiazide|Hydrochlorothiazide (HCTZ)]] | ||
* [[ | * [[IDRA-21]] | ||
* [[ | * [[LY-392098]] | ||
* [[ | * [[LY-395153]] | ||
* [[ | * [[LY-404187]] | ||
* [[ | * [[LY-451646]] | ||
* [[ | * [[LY-503430]] | ||
* [[ | * [[Mibampator|Mibampator (LY-451395)]] | ||
* [[ | * [[Nooglutyl]] | ||
* [[ | * [[ORG-26576]] | ||
* [[ | * [[Oxiracetam]] | ||
* [[ | * [[PEPA (drug)|PEPA]] | ||
* [[ | * [[Pesampator|Pesampator (BIIB-104, PF-04958242)]] | ||
* [[ | * [[Piracetam]] | ||
* [[ | * [[Pramiracetam]] | ||
* [[ | * [[S-18986]] | ||
* [[Tulrampator|Tulrampator (S-47445, CX-1632)]] | |||
* '' ' | * '''Antagonists:''' [[ACEA-1011]] | ||
* [[ | * [[ATPO]] | ||
* [[ | * [[Becampanel]] | ||
* [[ | * [[Caroverine]] | ||
* [[ | * [[CNQX]] | ||
* [[ | * [[Dasolampanel]] | ||
* [[ | * [[DNQX]] | ||
* [[ | * [[Fanapanel|Fanapanel (MPQX)]] | ||
* [[ | * [[gamma-D-Glutamylaminomethylsulfonic acid|GAMS]] | ||
* [[ | * [[Kaitocephalin]] | ||
* [[ | * [[Kynurenic acid]] | ||
* [[ | * [[Kynurenine]]<!--As a prodrug of kynurenic acid--> | ||
* [[ | * [[Licostinel|Licostinel (ACEA-1021)]] | ||
* [[ | * [[NBQX]] | ||
* [[ | * [[PNQX]] | ||
* [[ | * [[Selurampanel]] | ||
* [[ | * [[Tezampanel]] | ||
* [[ | * [[Theanine]] | ||
* [[ | * [[Topiramate]] | ||
* [[ | * [[YM90K]] | ||
* [[ | * [[Zonampanel]]; ''Negative allosteric modulators:'' [[Barbiturates]] (e.g., [[pentobarbital]], [[sodium thiopental]]) | ||
* [[ | * [[Cyclopropane]] | ||
* [[ | * [[Enflurane]] | ||
* [[ | * [[Alcohol (drug)|Ethanol (alcohol)]] | ||
* [[ | * [[Evans blue (dye)|Evans blue]] | ||
* [[ | * [[GYKI 52466|GYKI-52466]] | ||
* [[ | * [[GYKI-53655]] | ||
* [[ | * [[Halothane]] | ||
* [[ | * [[Irampanel]] | ||
* [[ | * [[Isoflurane]] | ||
* [[ | * [[Perampanel]] | ||
* [[ | * [[Pregnenolone sulfate]] | ||
* [[ | * [[Sevoflurane]] | ||
* [[ | * [[Talampanel]]; ''Unknown/unsorted antagonists:'' [[Minocycline]] | ||
* '' ' | | group2 = {{abbrlink|KAR|Kainate receptor}} | ||
* [[ | | list2 = | ||
* [[ | * '''Agonists:''' ''Main site agonists:'' [[5-Bromowillardiine]] | ||
* [[ | * [[5-Iodowillardiine]] | ||
* [[ | * [[Acromelic acid|Acromelic acid (acromelate)]] | ||
* [[ | * [[AMPA]] | ||
* [[ | * [[ATPA]] | ||
* [[ | * [[Domoic acid]] | ||
* [[ | * [[Glutamate]] | ||
* [[ | * [[Ibotenic acid]] | ||
* [[ | * [[Kainic acid]] | ||
* [[ | * [[LY-339434]] | ||
* [[ | * [[Proline]] | ||
* [[ | * [[Quisqualic acid]] | ||
* [[ | * [[SYM-2081]]; ''Positive allosteric modulators:'' [[Cyclothiazide]] | ||
* [[ | * [[Diazoxide]] | ||
* [[ | * [[Enflurane]] | ||
* [[ | * [[Halothane]] | ||
* [[ | * [[Isoflurane]] | ||
* [[ | |||
* [[ | * '''Antagonists:''' [[ACEA-1011]] | ||
* [[CNQX]] | |||
* [[Dasolampanel]] | |||
* [[DNQX]] | |||
* [[gamma-D-Glutamylaminomethylsulfonic acid|GAMS]] | |||
* [[Kaitocephalin]] | |||
* [[Kynurenic acid]] | |||
* [[Licostinel|Licostinel (ACEA-1021)]] | |||
* [[LY-382884]] | |||
* [[NBQX]] | |||
* [[NS102]] | |||
* [[Selurampanel]] | |||
* [[Tezampanel]] | |||
* [[Theanine]] | |||
* [[Topiramate]] | |||
* [[UBP-302]]; ''Negative allosteric modulators:'' [[Barbiturates]] (e.g., [[pentobarbital]], [[sodium thiopental]]) | |||
* [[Enflurane]] | |||
* [[Alcohol (drug)|Ethanol (alcohol)]] | |||
* [[Evans blue (dye)|Evans blue]] | |||
* [[NS-3763]] | |||
* [[Pregnenolone sulfate]] | |||
| group3 = {{abbrlink|NMDAR|N-Methyl-D-aspartate receptor}} | |||
| list3 = | | list3 = | ||
* '''Agonists:''' ''Main site agonists:'' [[2-Amino-2-(3-hydroxy-5-methylisoxazol-4-yl)acetic acid|AMAA]] | * '''Agonists:''' ''Main site agonists:'' [[2-Amino-2-(3-hydroxy-5-methylisoxazol-4-yl)acetic acid|AMAA]] | ||
Latest revision as of 09:05, 15 December 2022
Initial visibility: currently defaults to autocollapse
To set this template's initial visibility, the |state= parameter may be used:
|state=collapsed:{{Ionotropic glutamate receptor modulators|state=collapsed}}to show the template collapsed, i.e., hidden apart from its title bar|state=expanded:{{Ionotropic glutamate receptor modulators|state=expanded}}to show the template expanded, i.e., fully visible|state=autocollapse:{{Ionotropic glutamate receptor modulators|state=autocollapse}}
If the |state= parameter in the template on this page is not set, the template's initial visibility is taken from the |default= parameter in the Collapsible option template. For the template on this page, that currently evaluates to autocollapse.
